| Issue Date | Title | Author(s) |
| 2015 | Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin | Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur ; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J. |
| 2016 | Real-World Comparison of Major Bleeding and Associated Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban or Warfarin | Amin, Alpesh; Keshishian, A; Xie L; Başer, Onur ; Price, K; Vo, L; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio, J |
| 2016 | Real-World Comparison of Major Bleeding Risk Among Untreated Non-Valvular Atrial Fibrillation Patients and Those Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin | Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur ; Price, K; Lien Vo; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio J. |
| 2017 | Risk of Stroke/Systemic Embolism, Major Bleeding and Associated Costs in Non-Valvular Atrial Fibrillation Patients Who Initiated Apixaban, Dabigatran or Rivaroxaban Compared With Warfarin in the United States Medicare Population | Amin, Alpesh; Lien Vo; Trocio, Jeffrey; Keshishian, A; Liu, Xianchen; Mardekian, Jack; Zhang, Qisu; Rosenblatt, Lisa; Dina, Oluwaseyi; Başer, Onur ; Le, Hannah |
